Six patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2038. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2038
Next term end
5
Patent families
When these terms end
Each bar runs from grant to computed term end. 2019 to 2044.
US 10,995,101
2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers
Mar 30, 2038
US 12,715,880
Macrocyclic Diamine Derivatives as Ent Inhibitors for the Treatment of Cancers, and Combination Thereof with Adenosine Receptor Antagonists
Jun 28, 2043
20242029203420392044
7 pending applications: term is not computable until grant.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2038 · High confidence
Also notable
Ends Jul 2038 · High confidence
Also notable
Ends Aug 2044 · High confidence
2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers
US 10,995,101
Cited by 6 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2038.
Anti-Tigit Antibodies
US 10,329,349
A family of 6 related applications built on the 2019 grant. Protection runs to 2038.
ANTI-TREM2 Antibodies and Methods of Use
US 12,492,255
Granted 2025. Too new for citation comparison; protection runs to 2044.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 25, 2026The maintenance fee for Anti-Tigit Antibodies (US 10,329,349) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
- 1 term has ended since Aug 18, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Anti-Tigit Antibodies (2018) | 2 in force | to Jul 2038 |
| ANTI-TREM2 Antibodies and Methods of Use | 1 in force | to Aug 2044 |
| Macrocyclic Diamine Derivatives as Ent Inhibitors for the Treatment of Cancers, and Combination Thereof with Adenosine Receptor Antagonists | 1 in force | to Jun 2043 |
| Anti-Tigit Antibodies (2021) | 1 in force | to Jul 2038 |
| 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | 1 in force | to Mar 2038 |
Patents held now
Soonest term end first.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,995,101 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers In force · High confidence | In force | High confidence | |
| US 10,329,349 | Anti-Tigit Antibodies In force · High confidence | In force | High confidence | |
| US 11,439,705 | Anti-Tigit Antibodies In force · High confidence | In force | High confidence | |
| US 12,312,401 | Anti-Tigit Antibodies In force · High confidence | In force | High confidence | |
| US 12,715,880 | Macrocyclic Diamine Derivatives as Ent Inhibitors for the Treatment of Cancers, and Combination Thereof with Adenosine Receptor Antagonists In force · High confidence | In force | High confidence | |
| US 12,492,255 | ANTI-TREM2 Antibodies and Methods of Use In force · High confidence | In force | High confidence |
Also on record, not counted in the 6: 2 patents ended · 7 applications pending · 13 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.